1. WHO Coronavirus (COVID-19) Dashboard: World Health Organization; 2021. https:// covid19.who.int. Accessed September 18, 2021.
2. Santos-Filho OA. Identification of potential inhibitors of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) main protease from non-natural and natural sources: a molecular docking study. J Braz Chem Soc. 2020; 31:2638–2643.
3. Ashish K, Nelin V, Raaijmakers H, Kim HJ, Singh C, Målqvist M. Increased immunization coverage addresses the equity gap in Nepal. Bull World Health Organ. 2017; 95:261–269.
4. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247:1465–8.
5. Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16: 1833–1840.
6. Thess A, Grund S, Mui BL, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015; 23:1456–1464.
7. Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves trans-lation of nucleoside-modified, protein -encoding mRNA. Nucleic Acids Res. 2011; 39:e142.
8. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17:261–279.
9. Doerfler W. Adenoviral vector DNA- and SARS-CoV-2 mRNA-Based COVID-19 vaccines: possible integration into the human genome - Are adenoviral genes expressed in vector-based vaccines? Virus Res. 2021; 302:198466.
10. Ayati N, Jesudason S, Berlangieri SU, Scott AM. Generalized lymph node activation after influenza vaccination on 18F FDG-PET/CT imaging, an important pitfall in PET interpretation. Asia Ocean J Nucl Med Biol. 2017; 5:148–150.
11. Ligtenberg AJM, Brand HS. What are the differences between the various COVID-19 vaccines? Ned Tijdschr Tandheelkd. 2021; 128 [Epub ahead of print].
12. Minamimoto R, Kiyomatsu T. Effects of COVID-19 vaccination on FDG-PET/CT imaging: a literature review. Glob Health Med. 2021; 3:129–133.
13. McIntosh LJ, Bankier AA, Vijayaraghavan GR, Licho R, Rosen MP. COVID-19 vaccination-related uptake on FDG PET/CT: an emerging dilemma and suggestions for management. AJR Am J Roentgenol. 2021 [Epub ahead of print].
14. Treglia G, Cuzzocrea M, Giovanella L, Elzi L, Muoio B. Prevalence and significance of hypermetabolic lymph nodes detected by 2-[18F] FDG PET/CT after COVID-19 vaccination: a systematic review and a meta-analysis. Pharmaceuticals (Basel). 2021; 14:E762.
15. Cohen D, Krauthammer SH, Cohen YC, et al. Correlation between BNT162b2 mRNA COVID-19 vaccine-associated hyper-metabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. Eur J Nucl Med Mol Imaging. 2021; 48:3540–3549.
16. Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of increased FDG PET/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination. Radiology. 2021; 300: E345–E347.
17. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021; 21:475–484.